Hologic (WBO:HOLX) Cyclically Adjusted Revenue per Share: € (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:HOLX Hologic Inc WBO:HOLX
57 GF Score
Price €65.50
GF Value €70.70
! 5 Warning Signs
View Full Analysis

What is Hologic Cyclically Adjusted Revenue per Share?

Hologic WBO:HOLX 57 Cyclically Adjusted Revenue per Share is € as of Dec. 2025. GuruFocus rates WBO:HOLX with a GF Score™ of 57/100 and a GF Value™ of €70.70. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Hologic's adjusted revenue per share for the three months ended in Dec. 2025 was €3.985. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is for the trailing ten years ended in Dec. 2025.

During the past 12 months, Hologic's average Cyclically Adjusted Revenue Growth Rate was 5.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 6.20% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 10.00% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 9.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Hologic was 15.20% per year. The lowest was 6.20% per year. And the median was 10.50% per year.

As of today (2026-09-22), Hologic's current stock price is €65.50. Hologic's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2025 was . Hologic's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Hologic was 7.36. The lowest was 3.05. And the median was 4.81.


Hologic  (WBO:HOLX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Hologic was 7.36. The lowest was 3.05. And the median was 4.81.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Hologic Cyclically Adjusted Revenue per Share Related Terms


Hologic Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Hologic's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hologic Cyclically Adjusted Revenue per Share Chart

Hologic Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Hologic Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

WBO:HOLX vs WST, COO, ALGN: Cyclically Adjusted Revenue per Share Comparison

For the Medical Instruments & Supplies subindustry, Hologic's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hologic Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Hologic's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Hologic's Cyclically Adjusted PS Ratio falls into.


WBO:HOLX
57GF Score
Hologic Inc WBO:HOLX
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hologic Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Hologic's adjusted Revenue per Share data for the three months ended in Dec. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=3.985/324.0540*324.0540
=3.985

Current CPI (Dec. 2025) = 324.0540.

Hologic Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201603 2.185 238.132 2.973
201606 2.250 241.018 3.025
201609 2.305 241.428 3.094
201612 2.396 241.432 3.216
201703 2.347 243.801 3.120
201706 2.547 244.955 3.369
201709 2.402 246.819 3.154
201712 2.393 246.524 3.146
201803 2.318 249.554 3.010
201806 2.510 251.989 3.228
201809 2.543 252.439 3.264
201812 2.673 251.233 3.448
201903 2.677 254.202 3.413
201906 2.801 256.143 3.544
201909 2.874 256.759 3.627
201912 2.848 256.974 3.591
202003 2.595 258.115 3.258
202006 2.863 257.797 3.599
202009 4.382 260.280 5.456
202012 5.158 260.474 6.417
202103 4.896 264.877 5.990
202106 3.751 271.696 4.474
202109 4.334 274.310 5.120
202112 5.026 278.802 5.842
202203 5.045 287.504 5.686
202206 3.717 296.311 4.065
202209 3.747 296.808 4.091
202212 4.227 296.797 4.615
202303 3.830 301.836 4.112
202306 3.663 305.109 3.890
202309 3.516 307.789 3.702
202312 3.923 306.746 4.144
202403 3.947 312.332 4.095
202406 3.973 314.175 4.098
202409 3.811 315.301 3.917
202412 4.127 315.605 4.237
202503 4.231 319.799 4.287
202506 4.006 322.561 4.025
202509 3.978 324.800 3.969
202512 3.985 324.054 3.985

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of € mean?
Hologic (WBO:HOLX) has a Cyclically Adjusted Revenue per Share of € as of Dec. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Hologic and its competitors.
Is Hologic's Cyclically Adjusted Revenue per Share too high?
Hologic's current Cyclically Adjusted Revenue per Share is €. Overall, Hologic has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Hologic's Cyclically Adjusted Revenue per Share compare to WST and COO?
Hologic's Cyclically Adjusted Revenue per Share of € can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Hologic and its competitors. Hologic's current Cyclically Adjusted Revenue per Share is €. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hologic stock overvalued right now?
Hologic (WBO:HOLX) has a current Cyclically Adjusted Revenue per Share of €. The stock's GF Value™ is €70.70, compared to a current price of €65.50 — trading 7.4% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €. Hologic's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Hologic (WBO:HOLX), the current Cyclically Adjusted Revenue per Share is € as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hologic (WBO:HOLX) Overvalued in 2026?

Based on GuruFocus' analysis, Hologic stock appears to be undervalued. The current stock price of €65.50 is trading 7.4% below its estimated GF Value™ of €70.70.

Key valuation signals for WBO:HOLX:

  • Cyclically Adjusted Revenue per Share:
  • GF Value™: €70.70 vs. price of €65.50 (7.4% below fair value)
  • GF Score™: 57/100 with 5 warning signs

No single metric tells the full story. See the WBO:HOLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hologic Business Description

Address 250 Campus Drive, Marlborough, MA, USA, 01752
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
57GF Score

Get the complete analysis for WBO:HOLX

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€65.50
Price
€70.70
GF Value